About
Oral Treatment for Alzheimer's
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (6)
Gregory Ho, JD
Spring Mountain Capital
Allyx Therapeutics
team_member
Paul Fonteyne, MBA
Co-Founder
Allyx Therapeutics
founder
Robert Bettigole, MBA
Elm Street Ventures
Allyx Therapeutics
team_member
Stephen Bloch, MD
CEO, Co-Founder
Allyx Therapeutics
executivefounder
Stephen Strittmatter, MD, PhD
Scientific Founder
Allyx Therapeutics
founder
Timothy Siegert, PhD
COO, Co-Founder
Allyx Therapeutics
executivefounder
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
116
By Phase
PHASE1: 4
By Status
ACTIVE_NOT_RECRUITING: 2RECRUITING: 2
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06632990Lead Sponsor
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
PHASE1Active, not recruiting
36 participants
Started: Nov 4, 2024 · Completed: Oct 15, 2025
NCT06309147Lead Sponsor
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
PHASE1Recruiting
18 participants
Started: Mar 15, 2024 · Completed: Jul 15, 2025
NCT05804383Lead Sponsor
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
PHASE1Recruiting
50 participants
Started: Mar 28, 2023 · Completed: Jul 15, 2025
NCT05817643Lead Sponsor
Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers
PHASE1Active, not recruiting
12 participants
Started: Jan 10, 2023 · Completed: Nov 15, 2024
Locations (1)
Headquarters
New Haven, CT, United States
Map
Loading map...